APAC IPOs & Placements, Aequitas Research

Akshat Shah

APAC IPOs & Placements

IPOs and Placements coverage across Asia Pacific

Aequitas Research

We cover all listing across the Asia Pacific along with follow-up placements. As of Dec 2020, our team had covered 539 IPOs with a hit rate of 73.5% and 685 placements with a hit rate of 66.8%.

We combine fundamental bottom-up views with our proprietary quantitative framework to provide a holistic coverage across new listings and placements. Our coverage includes pre-IPO notes before the deal is launched, follow-up analysis once the deal is live and post-listing trading analysis as well.

Equity Capital Markets

Dorf-Ketal Chemicals Ltd / Equity Capital Markets

<ul>
<li>
<a href="https://www.smartkarma.com/entities/dorf-ketal-chemicals-ltd" target="_blank" data-smartkarma-citation="entities:44325:1" rel="noopener">Dorf-Ketal Chemicals Ltd (998552Z IN)</a> (DKCI) is looking to raise about US$579m in its upcoming India IPO.</li>
<li>DKCI is an R&amp;D and innovation-focused global manufacturer and supplier of specialty chemicals, catering to hydrocarbons and industrial supply chains, and customers with diverse applications across various industrial segments.</li>
<li>In this note, we talk about the positive aspects of the deal.</li>
</ul>



Dorf-Ketal Chemicals Ltd (998552Z IN) (DKCI) is looking to raise about US$579m in its upcoming India IPO.
DKCI is an R&amp;D and innovation-focused global manufacturer and supplier of specialty chemicals, catering to hydrocarbons and industrial supply chains, and customers with diverse applications across various industrial segments.
In this note, we talk about the positive aspects of the deal.


Dorf-Ketal Chemicals India Pre-IPO -The Positives - Strategic Blend of Organic & Inorganic Expansion

External broker reports(aggregated public sources), Axis Direct

Axis Direct

External broker reports(aggregated public sources)

Axis Direct is the flagship brand under Axis Securities Limited, a subsidiary of Axis Bank in India. 

Content available is external broker reports authored by a third party outside the Smartkarma network and has been aggregated by an online aggregator through publicly available sources and is displayed by Smartkarma in this format for user's convenience and general informational purposes only. Content does not constitute investment or financial advice and Smartkarma makes no representation or warranty regarding its accuracy or contents. Original third party author retains all copyright and other proprietary rights in the content. Access or use of third party links not controlled by Smartkarma are at the user's own risk.

Thematic (Sector/Industry)

<ul><li>Cement demand is expected to grow 10% YoY: After a subdued H1FY25 (2- 3% YoY growth), cement demand exhibited improvement in Q3FY25, growing in high single digits, and the momentum is expected to continue in Q4, driven by enhanced government capital expenditure and a rebound in construction activities post-monsoon.</li><li>The overall performance for the first nine months of FY25 remained subdued, with demand growth around 3-4% YoY.</li><li>Cement demand in India has shown resilience, particularly in Q4FY25, following a strong December 2024. </li></ul><p><em>Content is external broker report sourced from online content aggregator through publicly available sources and is displayed below for general informational purposes only. Refer full disclaimer below.</em></p>

Cement demand is expected to grow 10% YoY: After a subdued H1FY25 (2- 3% YoY growth), cement demand exhibited improvement in Q3FY25, growing in high single digits, and the momentum is expected to continue in Q4, driven by enhanced government capital expenditure and a rebound in construction activities post-monsoon.The overall performance for the first nine months of FY25 remained subdued, with demand growth around 3-4% YoY.Cement demand in India has shown resilience, particularly in Q4FY25, following a strong December 2024. Content is external broker report sourced from online content aggregator through publicly available sources and is displayed below for general informational purposes only. Refer full disclaimer below.

Market & Forensics Analyst, Beat the Street

Nimish Maheshwari

Market & Forensics Analyst

Beat the Street

Beat The Street was founded by Nimish Maheshwari and Sudarshan Bhandari, both of whom are Chartered Accountants by Profession, known for their expert analysis in the fields of Business, Sectoral analysis, and Corporate governance.

With a strong social media presence of 45,000+ Subscribers across various platforms, they are considered trusted voices in the industry. Their insights and analysis have been featured in some of India’s most prominent publications, including the Economic Times, Dalal Street Investment Journal, The Morning Context, and The Ken.

Their analysis on Bankrupt & Insolvent companies has been instrumental in saving investors from significant losses. They have a keen eye for identifying red flags and has identified exclusive redflags earlier in Vedanta, Nykaa, Dhani Services, Adani and many more.

Read Business Not Stock Prices

Equity Bottom-Up

<ul>
<li>Investors should keep a close eye on Adani's execution timeline, the impact on valuations in the sector, and the fundamentals of existing players in the C&amp;W industry. </li>
<li>While Adani's entry may bring some disruption, the sector's strong growth prospects and the resilience of leading players suggest that there is still value to be found. </li>
<li>In the end, long-term success in this industry will depend on a combination of strategic vision, operational excellence, and the ability to adapt to changing market dynamics.</li>
</ul>


Investors should keep a close eye on Adani's execution timeline, the impact on valuations in the sector, and the fundamentals of existing players in the C&amp;W industry. 
While Adani's entry may bring some disruption, the sector's strong growth prospects and the resilience of leading players suggest that there is still value to be found. 
In the end, long-term success in this industry will depend on a combination of strategic vision, operational excellence, and the ability to adapt to changing market dynamics.


What Does Adani’s Foray into Wires & Cables Mean for Investors and the Industry?

Anthem Biosciences / Equity Capital Markets

<ul>
<li>
<a href="https://www.smartkarma.com/entities/anthem-biosciences" target="_blank" data-smartkarma-citation="entities:44206:1" rel="noopener">Anthem Biosciences (1234D IN)</a> is looking to raise up to US$400m in its upcoming India IPO.</li>
<li>Anthem Biosciences (ABS) is a contract research, development and manufacturing organisation (CRDMO) with fully integrated operations spanning drug discovery, development, and manufacturing.</li>
<li>In this note, we talk about the not-so-positive aspects of the deal.</li>
</ul>



Anthem Biosciences (1234D IN) is looking to raise up to US$400m in its upcoming India IPO.
Anthem Biosciences (ABS) is a contract research, development and manufacturing organisation (CRDMO) with fully integrated operations spanning drug discovery, development, and manufacturing.
In this note, we talk about the not-so-positive aspects of the deal.


Anthem Biosciences Pre-IPO - The Negatives- Margins Aren't There Yet

<ul>
<li>
<a href="https://www.smartkarma.com/entities/anthem-biosciences" target="_blank" data-smartkarma-citation="entities:44206:1" rel="noopener">Anthem Biosciences (1234D IN)</a> is looking to raise up to US$400m in its upcoming India IPO.</li>
<li>Anthem Biosciences (ABS) is a contract research, development and manufacturing organisation (CRDMO) with fully integrated operations spanning drug discovery, development, and manufacturing.</li>
<li>In this note, we talk about the positive aspects of the deal.</li>
</ul>



Anthem Biosciences (1234D IN) is looking to raise up to US$400m in its upcoming India IPO.
Anthem Biosciences (ABS) is a contract research, development and manufacturing organisation (CRDMO) with fully integrated operations spanning drug discovery, development, and manufacturing.
In this note, we talk about the positive aspects of the deal.


Anthem Biosciences Pre-IPO - The Positives - Portfolio Expansion, Increasing Capacity to Fuel Growth

India

Ultra Tech Cement Ltd. produces a wide range of cement products. This Company represents the cement operations of Larsen & Toubro which were spun-off into a separate entity in which Grasim Industries holds a majority interest.

Price Gauge
52-week Range	0.00 - 0.00
Market Cap (USDm)	0.00
P/E	0.00
Dividend (Yield)	0.00

Ultratech Cement (UTCEM IN)

Dorf-Ketal Chemicals India Pre-IPO -The Positives - Strategic Blend of Organic & Inorganic Expansion

Dorf-Ketal Chemicals India is looking to raise about US$579m in its upcoming India IPO. In this note, we talk about the positive aspects of the deal.

Akshat Shah

Q4FY25 Earnings Preview - CEMENT

Cement demand is expected to grow 10% YoY: After a subdued H1FY25 (2- 3% YoY growth), cement demand exhibited improvement in Q3FY25, growing in...

Axis Direct

What Does Adani’s Foray into Wires & Cables Mean for Investors and the Industry?

Investors should monitor Adani's impact on valuations and existing players in the C&W industry, as success will hinge on strategic vision and...

Nimish Maheshwari

Anthem Biosciences Pre-IPO - The Negatives- Margins Aren't There Yet

Anthem Biosciences is looking to raise up to US$400m in its upcoming India IPO. In this note, we talk about the not-so-positive aspects of the deal.

Akshat Shah

Anthem Biosciences Pre-IPO - The Positives - Portfolio Expansion, Increasing Capacity to Fuel Growth

Anthem Biosciences is looking to raise up to US$400m in its upcoming India IPO. In this note, we talk about the positive aspects of the deal.

Akshat Shah

Price Gauge

52-week Range

Market Cap (USDm)

P/E

Dividend (Yield)

Dorf-Ketal Chemicals India Pre-IPO -The Positives - Strategic Blend of Organic & Inorganic Expansion

Dorf-Ketal Chemicals India is looking to raise about US$579m in its upcoming India IPO. In this note, we talk about the positive aspects of the deal.

Akshat Shah

Q4FY25 Earnings Preview - CEMENT

Cement demand is expected to grow 10% YoY: After a subdued H1FY25 (2- 3% YoY growth), cement demand exhibited improvement in Q3FY25, growing in...

Axis Direct

What Does Adani’s Foray into Wires & Cables Mean for Investors and the Industry?

​Investors should monitor Adani's impact on valuations and existing players in the C&W industry, as success will hinge on strategic vision and...

Nimish Maheshwari

Anthem Biosciences Pre-IPO - The Negatives- Margins Aren't There Yet

Anthem Biosciences is looking to raise up to US$400m in its upcoming India IPO. In this note, we talk about the not-so-positive aspects of the deal.

Akshat Shah

Anthem Biosciences Pre-IPO - The Positives - Portfolio Expansion, Increasing Capacity to Fuel Growth

Anthem Biosciences is looking to raise up to US$400m in its upcoming India IPO. In this note, we talk about the positive aspects of the deal.

Akshat Shah

Investors should monitor Adani's impact on valuations and existing players in the C&W industry, as success will hinge on strategic vision and...